Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Kaley
    Kaley
  3. Mellinghoff
    Mellinghoff
  4. Pentsova
    Pentsova
  5. Nolan
    Nolan
  6. Grommes
    Grommes
  7. Gavrilovic
    Gavrilovic
  8. Gutin
    Gutin
  9. Panageas
    Panageas
  10. Karimi
    Karimi

Groups

  1. Tow Center for Developmental Oncology (TCDO) (29)
  2. GSK Faculty (19)
  3. Human Oncology and Pathogenesis Program (16)
  4. Radiology, Department of (13)
  5. Neuroradiology Service (11)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  7. Biostatistics Service (8)
  8. Epidemiology and Biostatistics (8)
  9. Population Sciences Research Program (8)
  10. Center for Hematologic Malignancies (7)
Search Within
  1. "Antonio Omuro"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (20)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (29)
  2. GSK Faculty (19)
  3. Human Oncology and Pathogenesis Program (16)
  4. Radiology, Department of (13)
  5. Neuroradiology Service (11)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)

More Groups

People
  1. Antonio Omuro (68)
  2. Lisa De Angelis (25)
  3. Thomas Kaley (16)
  4. Ingo Mellinghoff (13)
  5. Lauren Abrey (13)
  6. Elena Pentsova (12)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2018 (1)
  5. 2017 (9)
  6. 2016 (8)

More Years

Publications
  1. Neuro-Oncology (63)
  2. Annals of Oncology (2)
  3. Neuro-Oncology Advances (2)
  4. Journal of Neuropathology and Experimental Neurology (1)

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
    Journal Article

    Omuro, A.; Brandes, A. A.; Carpentier, A. F.; Idbaih, A.; Reardon, D. A.; Cloughesy, T.; Sumrall, A.; Baehring, J.; van den Bent, M.; Bähr, O.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Journal Article

    Lim, M.; Weller, M.; Idbaih, A.; Steinbach, J.; Finocchiaro, G.; Raval, R. R.; Ansstas, G.; Baehring, J.; Taylor, J. W.; Honnorat, J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
    Journal Article

    Galanis, E.; Anderson, S. K.; Twohy, E.; Butowski, N. A.; Hormigo, A.; Schiff, D.; Omuro, A.; Jaeckle, K. A.; Kumar, S.; Kaufmann, T. J.; more...
    Neuro-Oncology Advances (2022)

    Fulltext@MSK | Save
  • Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Journal Article

    Omuro, A.; Reardon, D. A.; Sampson, J. H.; Baehring, J.; Sahebjam, S.; Cloughesy, T. F.; Chalamandaris, A. G.; Potter, V.; Butowski, N.; Lim, M.
    Neuro-Oncology Advances (2022)

    Fulltext@MSK | Save
  • Phase I and preliminary phase 0 results of ABTC 1801: A multi-arm clinical trial of the PARP inhibitor pamiparib (BGB290) with very low dose metronomic temozolomide in recurrent IDH mutant gliomas
    Meeting Abstract

    Schiff, D.; Bindra, R.; Li, J.; Ye, X.; Ellingson, B.; Walbert, T.; Campian, J.; Nabors, L. B.; Lieberman, F.; Ozer, B.; more...
    Neuro-Oncology (2021)

    Fulltext@MSK | Save
  • A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: Checkmate 548
    Meeting Abstract

    Weller, M.; Lim, M.; Idbaih, A.; Steinbach, J.; Finocchiaro, G.; Raval, R.; Ashby, L.; Ansstas, G.; Baehring, J.; Taylor, J.; more...
    Neuro-Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Journal Article

    Omuro, A.; Vlahovic, G.; Lim, M.; Sahebjam, S.; Baehring, J.; Cloughesy, T.; Voloschin, A.; Ramkissoon, S. H.; Ligon, K. L.; Latek, R.; more...
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (nivo) in combination with radiotherapy (RT) +/- temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Lim, M.; Omuro, A.; Vlahovic, G.; Reardon, D. A.; Sahebjam, S.; Cloughesy, T.; Baehring, J.; Butowski, N.; Potter, V.; Zwirtes, R.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Cerebrospinal fluid circulating tumor cells: A novel tool to diagnose leptomeningeal metastases from epithelial tumors
    Journal Article

    Lin, X.; Fleisher, M.; Rosenblum, M.; Lin, O.; Boire, A.; Briggs, S.; Bensman, Y.; Hurtado, B.; Shagabayeva, L.; DeAngelis, L. M.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
    Journal Article

    Thomas, A. A.; Abrey, L. E.; Terziev, R.; Raizer, J.; Martinez, N. L.; Forsyth, P.; Paleologos, N.; Matasar, M.; Sauter, C. S.; Moskowitz, C.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save